Titan Biotech Limited Board to Consider Q2 FY27 Results Nov 5

Titan Biotech Limited’s board is scheduled to consider unaudited Q2 FY27 standalone and consolidated results on November 5, 2026, following June-quarter standalone net sales growth of 27.3% year-on-year to ₹59.17 crore and reported profit after tax of ₹9.46 crore.

What will Titan Biotech consider at its November 5 board meeting?

Titan Biotech will consider and approve its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company has scheduled its board meeting for November 5, 2026, which is also identified as the expected earnings date in the available disclosures.

The announcement concerns the July-September 2026 quarter, or Q2 FY27, and the first half of FY27. The company has not disclosed the Q2 financial figures in the information provided. Investors will therefore be awaiting the reported revenue, profitability, margin and balance-sheet data after the board completes its review.

The meeting follows Titan Biotech’s first-quarter performance for the year. The company’s reported Q1 FY27 standalone total income was ₹60.98 crore, while net sales were ₹59.17 crore. Its reported profit after tax for the period was ₹9.46 crore.

Why was Titan Biotech’s trading window closed before the results?

Titan Biotech closed its trading window from October 1, 2026, ahead of the release of financial results for the quarter and half-year ended September 30, 2026. The closure restricts insiders from trading in the company’s securities during the specified period under applicable insider-trading compliance requirements.

The window closure was announced as a key event in advance of the Q2 FY27 results. Such restrictions are intended to prevent persons with access to unpublished price-sensitive information from trading before the results are publicly released.

No additional details on the duration of the closure or any market activity during the closed period were provided. The disclosed purpose is linked directly to the upcoming unaudited results and the associated compliance process.

How did Titan Biotech perform in Q1 FY27?

Titan Biotech’s Q1 FY27 standalone net sales increased 27.3% year-on-year to ₹59.17 crore, from ₹46.50 crore in the June 2025 quarter. Total income rose to ₹60.98 crore from ₹47.22 crore, based on the quarterly financial data provided.

Operating profit was ₹12.49 crore in the June 2026 quarter, compared with ₹8.74 crore a year earlier. The operating profit margin improved to 21.85% from 17.87%. Reported profit after tax rose to ₹9.46 crore from ₹6.16 crore, while cash profit increased to ₹10.83 crore from ₹7.31 crore.

A separate earnings summary stated Q1 FY27 revenue of ₹609.8 million, equivalent to ₹60.98 crore, and net income of ₹108.6 million, equivalent to ₹10.86 crore. The standalone quarterly statement lists total income of ₹60.98 crore and reported profit after tax of ₹9.46 crore. The provided material identifies the detailed quarterly statement as standalone, while the board meeting will review both standalone and consolidated results.

What does the recent quarterly trend show for Titan Biotech?

Titan Biotech’s standalone net sales moved from ₹46.50 crore in June 2025 to ₹54.35 crore in September 2025, ₹56.51 crore in December 2025, ₹48.83 crore in March 2026 and ₹59.17 crore in June 2026. The June 2026 figure was the highest net-sales figure across the five quarters shown in the provided data.

Operating profit also increased over the same comparison period, rising from ₹8.74 crore in June 2025 to ₹12.49 crore in June 2026. The operating profit margin expanded from 17.87% to 21.85%, while reported profit after tax rose from ₹6.16 crore to ₹9.46 crore.

For the year ended March 2026, Titan Biotech reported sales of ₹206.19 crore, operating profit of ₹38.60 crore and profit after tax of ₹27.45 crore. This compared with sales of ₹156.45 crore, operating profit of ₹25.43 crore and profit after tax of ₹18.27 crore for the year ended March 2025.

The March 2026 annual operating profit margin was 18.72%, compared with 16.25% in March 2025. These historical figures provide a context for assessing whether the June-quarter improvement in sales and operating profitability continues in the September quarter.

What should investors assess in Titan Biotech’s Q2 FY27 results?

Investors can assess whether Titan Biotech has sustained the revenue and operating-margin progress reported in Q1 FY27. The September-quarter release will provide the first disclosed financial update after June-quarter net sales of ₹59.17 crore and operating profit margin of 21.85%.

The half-year results will also allow comparison of first-half FY27 performance with the reported June-quarter numbers and the company’s recent quarterly record. Because the company will release both standalone and consolidated statements, readers should distinguish between the two sets of figures when reviewing sales, profit and other financial metrics.

The board meeting is important because the company’s latest reported financial information in the supplied material relates to the June 2026 quarter. The November 5 disclosure is expected to update shareholders on the September 2026 quarter and give a reported view of performance during the first six months of FY27.

Conclusion

Titan Biotech’s November 5 board meeting is focused on approving unaudited Q2 FY27 and half-year financial results. The update follows a June 2026 standalone quarter in which net sales reached ₹59.17 crore, operating profit was ₹12.49 crore and reported profit after tax stood at ₹9.46 crore.

The main point to watch is the official Q2 FY27 release after the board meeting, particularly the reported standalone and consolidated sales, operating profit margins and profit figures. The company has disclosed the meeting date and the trading-window closure, but has not yet provided September-quarter financial results.